Allorion Therapeutics inks $40m Series A

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, has secured $40 million in Series A financing.

Allorion Therapeutics, a company focusing on next-generation precision medicine for oncology and autoimmune disease, has secured $40 million in Series A financing. Qiming Venture Partners led the round with participation from IDG Capital, Octagon Capital, Firstred Capital, Elikon Venture, TF Capital and Med-Fine Capital.

Source: Press Release